Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Haven't seen the link posted here yet, but full videa can be seen here. Inhaled interferon move to P3 at about 10:50, and confirmation that he meant SNG at 24:50
https://twitter.com/Tyza1971/status/1404798411753275397
Not starting a trial - confirming that the USA wide P2 trial of SNG001 has been moved to P3 with more patients. With other drugs in P3 the US has placed large orders in advance of EUA should it be granted.
https://www.merck.com/news/merck-announces-supply-agreement-with-u-s-government-for-molnupiravir-an-investigational-oral-antiviral-candidate-for-treatment-of-mild-to-moderate-covid-19/
Read the sharing rules more carefully - I can share the whole thing :)
https://rdcu.be/cmdx8
I can access the paper but due to copyright can't repost all of it here - however here is the conclusion:
Insight that type I IFN defects underlie severe COVID-19 in at least 10% of patients challenges past, ongoing, and future trials and clinical treatment strategies. Here, we discussed how findings from the COVIDhge provide a rationale for targeted interventions during specific phases of COVID-19 pathogenesis. Early testing can identify individuals with defects in the type I IFN circuit, whether genetically or serologically mediated, who stand to most benefit from IFN-ß therapy prior to or during the early viral replication phase. In addition, the efficacy of IFN-ß therapy would not be anticipated to be affected by the infecting SARS-CoV-2 variant. Those hospitalized and found to harbor neutralizing auto-Abs to type I IFN might benefit from TPE. Ideally, trials should be designed to specifically address these different treatment groups. Our findings also raise important questions about some of the current approaches being evaluated, e.g., the use of convalescent plasma and the use of Jakinibs. Finally, despite the advent of efficacious vaccines in the general population, patients with defects of type I IFN immunity may continue to remain at risk, for example, due to impaired innate responses in the face of emerging variants or to sub-optimal adaptive immunity. The ongoing work of our consortium, in conjunction with the recent promising results of IFN-ß in treatment of SARS-CoV-2 infection, opens bold new avenues in the global fight against this pandemic.
TL you are right to be wary. Twitter is useful as a sentiment check for traders, but of limited use for investors. Myles McNulty is an exception to this as he's an interesting fellow and well worth looking at what he's interested in as he's typically in for the long run.
Was umming and ahing when it was hovering around a £, but decided to stick with some other opportunities thinking it could stay there for a while. Well done to those who went for it! As it is my main holding is looking a lot better again.
Read that too - sounds like steroids are seeing some major complications, but not the only cause with lots of it being down to over stretched staff and hospital resources. Sounds pretty scary.